U.S., March 7 -- ClinicalTrials.gov registry received information related to the study (NCT07454382) titled 'A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma' on March 02.
Brief Summary: The purpose of this study is to find out whether the combination of elranatamab and cyclophosphamide is an effective treatment for people with relapsed/refractory multiple myeloma (MM) who have risk factors that may affect how well their disease would respond to elranatamab alone.
Study Start Date: Feb. 27
Study Type: INTERVENTIONAL
Condition:
Multiple Myeloma
Intervention:
BIOLOGICAL: Elranatamab-bcmm
Elranatamab-bcmm is a recombinant, humanized, bispecific IgG2 kappa antibody
DRUG: Cyclophosphamide
Cyclophosphamide is ...